Laila Carolina Abu Esba1,2,3, Majed Al Jeraisy1,2,3. 1. Pharmaceutical Care Services, Ministry of the National Guard - Health Affairs, Riyadh, Saudi Arabia. 2. King Abdullah International Medical Research Center, Riyadh, Saudi Arabia. 3. Collage of Pharmacy, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.
Abstract
Objectives: Several cases of unusual thrombotic events with thrombocytopenia were reported in several countries, in association with AstraZeneca's COVID-19 vaccine. The European medicines agency conducted a detailed review and concluded that there was no evidence to suggest an association of thrombotic events with the use of COVID-19 vaccine AstraZeneca. Methods: King Abdulaziz Medical City is a 1500 bed tertiary care hospital in Riyadh, Saudi Arabia; this study describes spontaneously reported vaccine adverse effects received through the hospital's internal electronic safety reporting system from December 2020 to 13 April 2021.We assessed each report for causality association utilizing the world health organization's (WHO) causality assessment of an adverse event following immunization (AEFI) classification 2nd Edition 2019. Results: The majority of the reported events were mild to moderate, there were five serious events, one reported cardiac arrest, two cerebral venous sinus thrombosis, and two pulmonary embolism. Clinical and laboratory summary of the five patients are presented in detail.Conclusions: Efforts of pharmacovigilance in mediating the rare risk of thrombosis associated with COVID-19 vaccine are crucial in providing awareness on the possible risk factors and signs/symptoms that should raise red flags.
Objectives: Several cases of unusual thrombotic events with thrombocytopenia were reported in several countries, in association with AstraZeneca's COVID-19 vaccine. The European medicines agency conducted a detailed review and concluded that there was no evidence to suggest an association ofthrombotic events with the use ofCOVID-19 vaccine AstraZeneca. Methods: King Abdulaziz Medical City is a 1500 bed tertiary care hospital in Riyadh, Saudi Arabia; this study describes spontaneously reported vaccine adverse effects received through the hospital's internal electronic safety reporting system from December 2020 to 13 April 2021.We assessed each report for causality association utilizing the world health organization's (WHO) causality assessment of an adverse event following immunization (AEFI) classification 2nd Edition 2019. Results: The majority of the reported events were mild to moderate, there were five serious events, one reported cardiac arrest, two cerebral venous sinus thrombosis, and two pulmonary embolism. Clinical and laboratory summary of the five patients are presented in detail.Conclusions: Efforts of pharmacovigilance in mediating the rare risk ofthrombosis associated with COVID-19 vaccine are crucial in providing awareness on the possible risk factors and signs/symptoms that should raise red flags.
Authors: Rave Harpaz; William DuMouchel; Robbert Van Manen; Alexander Nip; Steve Bright; Ana Szarfman; Joseph Tonning; Magnus Lerch Journal: Drug Saf Date: 2022-06-23 Impact factor: 5.228
Authors: Philipp Fervers; Jonathan Kottlors; Thorsten Persigehl; Simon Lennartz; Volker Maus; Sebastian Fischer; Hanna Styczen; Cornelius Deuschl; Marc Schlamann; Anastasios Mpotsaris; Seraphine Zubel; Michael Schroeter; David Maintz; Gereon Rudolf Fink; Nuran Abdullayev Journal: J Clin Neurosci Date: 2022-06-06 Impact factor: 2.116
Authors: Cesare de Gregorio; Luigi Colarusso; Giuseppe Calcaterra; Pier Paolo Bassareo; Antonio Ieni; Anna Teresa Mazzeo; Giuseppe Ferrazzo; Alberto Noto; Ioanna Koniari; Jawahar L Mehta; Nicholas G Kounis Journal: Vaccines (Basel) Date: 2022-02-03
Authors: Ma'mon M Hatmal; Mohammad A I Al-Hatamleh; Amin N Olaimat; Rohimah Mohamud; Mirna Fawaz; Elham T Kateeb; Omar K Alkhairy; Reema Tayyem; Mohamed Lounis; Marwan Al-Raeei; Rasheed K Dana; Hamzeh J Al-Ameer; Mutasem O Taha; Khalid M Bindayna Journal: Vaccines (Basel) Date: 2022-02-26